Skip to main content

Follow us

Home

Search

the Gateway to Research in Oklahoma

  • Researchers
  • Providers
  • Patients
  • About GRO

Gateway to Research in Oklahoma


Oklahoma Shared Clinical and Translational Resources U54 GM104938

Researchers

imgResearchers

The GRO: Researcher Portal provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in Oklahoma.

Providers

imgProviders

The GRO: Provider Portal assists medical providers to identify clinical research opportunities in Oklahoma, tools for patient education, and evidence-based resources to improve patient care.

Patients

imgPatients

The GRO: Patient Portal can help patients and families to learn more about clinical and translational research and to connect with opportunities to participate in research opportunities in your communities.

Oklahoma Research Highlights

Magnetic removal of fragmented Crawford hook during nasolacrimal duct probing

3 months 2 weeks ago
We present the case of a 13-month-old girl with Down syndrome who underwent probing to alleviate nasolacrimal duct obstruction (NLDO). During the procedure, a distal portion of the deployed Crawford hook fragmented and became lodged in the right nasopharynx. Traditional intraoperative methods of visualization were unsuccessful; however, extraction of the fragment was achieved by using a nasogastric bridle magnet. This case demonstrates a novel method of metallic foreign body removal, which may...
Sang Nguyen

IgA2<sup>+</sup> B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus

3 months 2 weeks ago
No theragnostic biomarkers exist for systemic lupus erythematosus (SLE) to enable a precision medicine approach. Baseline serum IgA2 anti-double-stranded DNA (dsDNA) antibody levels are associated with response to combination belimumab after rituximab therapy in SLE (BEAT-lupus trial, ISRCTN 47873003). Analysis of the CALIBRATE trial (NCT02260934) confirms that baseline IgA2 anti-dsDNA antibody levels are specifically associated with response to belimumab after rituximab (odds ratio [OR] = 16.9,...
Daniel McCluskey

Breaking free from opioids: A turning point in acute pain management

3 months 2 weeks ago
No abstract
Khaled S Abd-Elrahman

Why do bootlickers get empowered more than boat-rockers? The effects of voice and helping on empowering leadership through threat and goal congruence perceptions

3 months 2 weeks ago
As empowering leadership becomes increasingly needed in today's complex organizations, so does the need to understand what motivates leaders to give more (or less) empowering leadership to followers. We draw on threat rigidity theory to examine how followers' challenging and supportive voice differentially impact the extent to which leaders empower their followers. We argue that leaders perceive followers' challenging voice as more threatening and tend to empower them less, whereas leaders...
Troy A Smith

Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort

3 months 2 weeks ago
CONCLUSION: T2 immune responses were associated with lower virus loads and more favorable clinical outcomes, suggesting that T2 inflammation related to asthma and allergic diseases may have a direct protective effect against SARS-CoV-2.
Naresh Doni Jayavelu

Pagination

  • Previous page ‹ Previous
  • Page 6
  • Next page Next ›
Subscribe to

octsi logo

1000 N. Lincoln Blvd, Suite 2100, Oklahoma City, OK 73104
Copyright © 2021 The Board of Regents of the University of Oklahoma, All Rights Reserved.

About GRO

News
Publications
FAQ

Terms of Use

Privacy Policy
Accessibility

Contact

info email
info phone
Copyright © 2025. All rights reserved. Designed By Zymphonies